Breaking Cancer's Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy.
Date
Authors
Supervisor
Item type
Journal Article
Degree name
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI AG
Abstract
CDK4/6 inhibition represents a new generation of cancer therapies, targeting CDK4/6 complexes to induce cell cycle arrest in the G1 phase. These inhibitors have been widely used in combination with hormone receptor antagonists for treating ER+/HER2- breast cancer, achieving significant clinical success. Building on this progress, ongoing research explores novel combination therapies and expands the application of CDK4/6 inhibitors to other diseases. However, challenges remain, including variable cellular responses and the rapid development of drug resistance. Recent studies have uncovered new resistance mechanisms and their unexpected effects on cell metabolism, autophagy, and the tumor microenvironment beyond cell cycle arrest. This review provides a comprehensive overview of the mechanisms by which CDK4/6 inhibitors combat cancer and explores their potential for more effective and personalized treatment strategies.Description
Keywords
CDK 4/6 inhibitor, cancer treatment, combination therapy, 32 Biomedical and Clinical Sciences, 3211 Oncology and Carcinogenesis, Cancer, Women's Health, Breast Cancer, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, 2.1 Biological and endogenous factors, Cancer, 3 Good Health and Well Being, 1112 Oncology and Carcinogenesis, 3211 Oncology and carcinogenesis
Source
Cancers (Basel), ISSN: 2072-6694 (Print); 2072-6694 (Online), MDPI AG, 17(12), 1941-1941. doi: 10.3390/cancers17121941
Publisher's version
Rights statement
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).